Joslin in National Diabetes Trial on Sensor-Augmented Pump Therapy
Tuesday, June 29, 2010
Clinical research conducted at Joslin Diabetes Center and 29 other sites in the U.S. and Canada showed adult and pediatric patients with type 1 diabetes achieved better blood glucose control by using a sensor-augmented insulin pump compared to multiple daily insulin injections.
The significant improvement in blood glucose levels observed in the STAR 3 (Sensor-Augmented Pump Therapy for A1C Reduction) trial occurred without an increase in the rate of hypoglycemia (low blood glucose), the most prevalent clinical risk with intensive insulin management.
“The demonstration of a significant 0.6% reduction in A1C for youth and adults in the STAR 3 trial is very encouraging,” commented Sanjeev Mehta, M.D., M.P.H., a STAR 3 investigator and Joslin staff physician and research associate. “The strong association between changes in A1C and adherence to sensor wear, however, reinforces the need to focus on resolving barriers to the sustained use of these devices for individuals with type 1 diabetes. We are encouraged by these findings and now look forward to opportunities to translate these benefits into the clinical care arena.”
News | Diabetes Research
Page last updated: January 17, 2017